Skip to main content



Seqbiome expert microbiome analysis partner on the first placebo-controlled trial of vaginal microbiota transplantation (VMT)

SeqBiome had the pleasure of being the expert microbiome analysis partner on the first placebo-controlled…
July 4, 2024

SeqBiome at Probiota Milan 2024

We can't wait to be a part of Probiota 2024, the leading Microbiome industry event…
February 8, 2024

Microbiome links with diabetes and cancer immunotherapy jointly published with Roche

Our CEO Marcus Claesson was the last author on a joint publication in Immuno Horizons…
January 15, 2024

Benefits of fermented foods reviewed in Nature journal

Our CTO Prof Paul Cotter was senior author on a recentĀ publicationĀ in Nature Reviews Gastroenterology and…
January 15, 2024

SeqBiome sponsors Boston conference

Our CEO Marcus Claesson is giving a talk about his group's research on the gut…
November 10, 2023

Our CTO discusses microbiome and performance with Real Madrid

At the 1st International Seminar on Nutrition and Sport for Abbott-Nutrition and Real-Madrid CF, our…
September 6, 2023

Our partner Freya Biosciences announces positive microbiome therapy for vaginal dysbiosis

We are delighted to have contributed to the positive outcomes from the Freya Bioscience's first…
June 26, 2023

Mapping gut microbiome transfer from mother to baby

Our CTO is the last author in a recently published study in Nature Communications, the…
June 12, 2023

SeqBiome sponsors conference on microbiome bioinformatics and machine learning

SeqBiome is proud to have sponsored a conference on the next-generation bioinformatics tools for microbiome…
June 10, 2023